Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3146MR)

This product GTTS-WQ3146MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3146MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15244MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ6567MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ1919MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ10706MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ1985MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ12975MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11454MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ2985MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANB020
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW